Department of Bioengineering, Graduate School of Engineering, The University of Tokyo, Bunkyo, Tokyo 113-8656, Japan; Innovation Center of NanoMedicine, Kawasaki Institute of Industrial Promotion, Kawasaki, Kanagawa 210-0821, Japan.
Department of Bioengineering, Graduate School of Engineering, The University of Tokyo, Bunkyo, Tokyo 113-8656, Japan; Innovation Center of NanoMedicine, Kawasaki Institute of Industrial Promotion, Kawasaki, Kanagawa 210-0821, Japan.
Biomaterials. 2018 Jan;150:162-170. doi: 10.1016/j.biomaterials.2017.09.033. Epub 2017 Sep 27.
Messenger (m)RNA vaccines require a safe and potent immunostimulatory adjuvant. In this study, we introduced immunostimulatory properties directly into mRNA molecules by hybridizing them with complementary RNA to create highly immunogenic double stranded (ds)RNAs. These dsRNA formulations, comprised entirely of RNA, are expected to be safe and highly efficient due to antigen expression and immunostimulation occurring simultaneously in the same antigen presenting cells. In this strategy, design of dsRNA is important. Indeed, hybridization using full-length antisense (as)RNA drastically reduced translational efficiency. In contrast, by limiting the hybridized portion to the mRNA poly A region, efficient translation and intense immunostimulation was simultaneously obtained. The immune response to the poly U-hybridized mRNAs (mRNA:pU) was mediated through Toll-like receptor (TLR)-3 and retinoic acid-inducible gene (RIG)-I. We also demonstrated that mRNA:pU activation of mouse and human dendritic cells was significantly more effective than activation using single stranded mRNA. In vivo mouse immunization experiments using ovalbumin showed that mRNA:pU significantly enhanced the intensity of specific cellular and humoral immune responses, compared to single stranded mRNA. Our novel mRNA:pU formulation can be delivered using a variety of mRNA carriers depending on the purpose and delivery route, providing a versatile platform for improving mRNA vaccine efficiency.
信使 (m)RNA 疫苗需要一种安全且有效的免疫刺激性佐剂。在本研究中,我们通过与互补 RNA 杂交将免疫刺激性特性直接引入 mRNA 分子,从而创建具有高度免疫原性的双链 (ds)RNA。由于抗原表达和免疫刺激同时在相同的抗原提呈细胞中发生,这些完全由 RNA 组成的 dsRNA 制剂有望安全且高效。在这种策略中,dsRNA 的设计很重要。事实上,使用全长反义 (as)RNA 进行杂交会大大降低翻译效率。相比之下,通过将杂交部分限制在 mRNA 的 poly A 区域,可同时获得有效的翻译和强烈的免疫刺激。针对 poly U 杂交 mRNA (mRNA:pU) 的免疫反应是通过 Toll 样受体 (TLR)-3 和视黄酸诱导基因 (RIG)-I 介导的。我们还证明,与使用单链 mRNA 相比,mRNA:pU 对小鼠和人树突状细胞的激活作用明显更有效。使用卵清蛋白进行的体内小鼠免疫实验表明,与单链 mRNA 相比,mRNA:pU 可显著增强特异性细胞和体液免疫反应的强度。我们的新型 mRNA:pU 制剂可根据目的和给药途径使用各种 mRNA 载体进行递送,为提高 mRNA 疫苗的效率提供了一个多功能平台。